| Speakers from |
 |
|
Ablynx
ActoGeniX NV
Aepodia
Aicuris
Almac
Aperio
AstraZeneca
Axxam S.p.A.
Basel
Baxter
Bayer Healthcare
Bayer-Schering Pharma
bioXell
Bristol Myers Squibb
Eli Lilly
Eisai
F. Hoffmann-La Roche
GlaxoSmithKline
GSK Biologics
Horizon Discovery
Human Genome Sciences
In-Motion Management
Maccine
MediGene AG
MedImmune
Merck KGaA
Metabolys
NNIT A/S
Novartis
Nycomed
Pfizer
Roche Products Ltd
Teva Pharmaceutical Industries
Tibotec-Virco
The Psychological Society
University of London
Wyeth
YM Biosciences
|
|
|
|
|
| Featured Speakers |
|
|
|
Wolfgang M. Baiker,
Corporate Head of Development, Boehringer Ingelheim
|
 |
|
|
James Bailey,
GSK Team Leader, Medicinal Chemsitry, GSK
|
|
|
|
Sophie Banzet,
Head of Safety Science CNS, Roche
|
|
|
|
Mireille Cantarini,
Internal Clinical genetics Expert, Astrazeneca
|
|
|
|
Thomas Colatsky,
Director Division of Applied Pharmacology Research and Acting Director Laboratory of Clinical Pharmacology, FDA
|
|
|
|
Lucette Doessegger,
Global Head Safety Licensing and Early Development, Roche
|
|
|
|
Martin Elmlinger,
Director Biomarkers, Nycomed
|
|
|
|
Angela, Flannery
Director, R&D Science Policy, Astrazeneca
|
|
|
|
Dr. Thomas Herget,
Senior Director R&D New Technology Evaluation Performance & Life Science Chemicals, Merck
|
|
|
|
Vicki Ikin,
Clinical Biomarker Scientist Group Manager, Astrazeneca
|
|
|
|
Bahija Jallal,
VP Translational Sciences, Medimmune
|
|
|
|
Jörg Kemkowski,
Vice President, Head of Institute of Pharmcology and Preclinical Drug Safety (IPAS), Nycomed GmbH
|
|
|
|
Farhad Khan,
Principal Scientist in Epidemiology, Novo Nordisk A/S
|
|
|
|
Roy Mansfield,
Director Safety and Risk Management, Pfizer
|
|
|
|
Dr. Julian C. Matthews,
Senior Lecturer in the School of Cancer and Imaging Sciences, University of Manchester
|
|
|
|
Howard Mellor,
Pre-Clinical Safety Scientist, General Toxicology Sciences, Safety Assessment UK, Astrazeneca
|
|
|
|
Alan, Morrison
VP International Regulatory Affairs, Amgen
|
|
|
|
David Nicholson,
SVP Global Research, Schering Plough
|
|
|
|
Taoufik Outas,
Senior Scientist - Exploratory Development Department, Astellas
|
|
|
|
Elke Persohn,
Head of Cellular Imaging Group, Novartis
|
|
|
|
Stefan Platz,
Head Toxicology and Global Head Early Safety, Hoffman la Roche
|
|
|
|
Marc Princivalle,
Director of Toxicology, Research and Preclinical Development & Head of Preclinical Rish Assessment, EMEA, Stiefel (GSK)
|
|
|
|
Eugenii Rabiner,
Director, Clinical Imaging Applications, GSK
|
|
|
|
Tino Rossi,
VP Preclinical Drug Discovery & Enabling Technologies, Neurosciences CEDD, GlaxoSmithKline
|
|
|
|
Thomas Steinbach,
Senior Director Safety Surveillance & Risk Management, Wyeth
|
|
|
|
Jean-Pierre, Valetin,
Director, Safety Pharmacology, Astrazeneca
|
|
|
|
Philippe Van der Auwera,
Global Head of Safety, Roche
|
|
|
|
Jingsong Wang,
Director Discovery Medicine & Clinical Pharmacology, Bristol Myers Squibb
|
|
|
|
Will Watson,
Senior Partnering Director, Teva Innovative ventures
|
|
|
|
Agnes Westelinck.
Regulatory Affairs, Roche
|
|
|
|
|
|
